Objective: This study evaluated the effects of Alzheimer disease (AD) on the relationship between the brain noradrenergic system and hypothalamic pituitary adrenocortical axis (HPA).
| INTRODUCTION
The relationships between the central nervous system (CNS) noradrenergic system and the hypothalamic pituitary adrenocortical (HPA) axis are complex, and the levels of at which these systems interact are multiple. Noradrenergic and adrenergic input to HPA axis activation can involve direct projections and indirect paths between brain structures and signaling through peripheral sympathetic input.
1,2 One significant pathway includes brainstem projections thought to provide the substantial proportion of regulatory input to corticotropin releasing factor-producing neurons in the paraventricular nucleus (PVN) of the hypothalamus. These include noradrenergic projections, the larger proportion from the nucleus of the solitary tract but also from the locus coeruleus (LC), 1 likely mediated through alpha-1 adrenoreceptors in the PVN. 3 Previous cerebrospinal fluid (CSF) studies suggest dysregulation of the HPA axis and the CNS noradrenergic system in Alzheimer disease (AD). Cross-sectional studies examining CSF cortisol have shown higher levels in older compared with younger participants, with even higher levels in older participants with AD. [4] [5] [6] Neurodegeneration of the LC with substantial neuronal loss and neurofibrillary tangle formation occurs early in the course of AD. 7, 8 Compensatory upregulation of norepinephrine (NE) biosynthetic capacity in surviving LC neurons and upregulation of noradrenergic postsynaptic receptors in AD 9,10 may contribute to the pathophysiology of agitation and aggression in AD. 11, 12 Given the role of CNS noradrenergic regulation of the HPA axis, we hypothesized that in normal controls, there would be a positive relationship between CSF cortisol and CSF NE. We also hypothesized that this relationship would be altered in AD dementia and aMCI.
Therefore, we examined the cross-sectional association between CSF cortisol and NE from samples in a large CSF repository. Our aims were to examine this relationship in cognitively normal controls and whether CSF cortisol and NE associations differed by presence of aMCI and AD dementia. We also added a sensitivity analysis combining AD dementia and aMCI in 1 group, based on the conceptualization that aMCI is the earliest clinical manifestation of AD.
2 | METHODS
| Study participants
We analyzed CSF samples and data from an existing CSF repository from an academic multicenter study. Study procedures pertaining to this repository and multicenter study have been previously described. 13, 14 The sites involved were the University of Washington, Association criteria for probable AD and had a CDR Scale of 1 or more.
The repository protocol required all participants be medically stable and have stable medications for 4 weeks prior to the lumbar puncture.
Exclusionary criteria included current substance use disorders, a current major depressive episode, and chronic psychiatric conditions such as schizophrenia, bipolar disorder, and posttraumatic stress disorder.
All procedures were approved by the institutional review boards for participating institutions, and all participants provided written informed consent before study enrollment.
| CSF collection
Sample collections occurred between 0900 and 1100 hours with participants fasting. Cerebrospinal fluid was divided into sequential 0.5-mL aliquots into polypropylene tubes, frozen immediately on dry ice at the bedside, and then stored at −70°C until assayed. Tubes assigned to the NE assay also contained the additive glutathione.
| NE and cortisol assays
For measurement of CSF NE concentration, CSF was extracted using the alumina extraction method optimized by Holmes et al. 18 Extracted samples were separated by high-pressure liquid chromatography using a reverse phase C-18 column and measured by electrochemical detection (Coulechem II, ESA, Inc, Chelmsford, Massachusetts) with 3,4-dihydroxybenzylamine as an internal standard. 14 The intra-assay coefficient of variation is 7.1% (based on measurements of the internal ref- was added to samples to bring their protein content roughly equivalent to the protein in the kit standards that are in a "human serum matrix."
| Statistical analysis
Linear regression was used to determine the association between CSF NE or CSF cortisol (the dependent variables) and age, and the association between the CSF variables and sex, education and body mass index (BMI) adjusting for age (ie, with linear age as a model covariate).
Key points
• There are known relationships between the noradrenergic system and hypothalamic pituitary adrenocortical (HPA) axis. How these relationships are affected by Alzheimer disease (AD) are unclear.
• This study evaluated relationships between cerebrospinal fluid (CSF) cortisol and CSF norepinephrine (NE) in controls, participants with amnestic mild cognitive impairment, and participants with AD dementia.
• CSF cortisol and CSF NE were not significantly associated in controls. However, higher CSF cortisol was associated with higher CSF NE in participants with AD, likely reflecting alterations in these systems in AD.
To determine if mean CSF cortisol or CSF NE levels differed by AD/aMCI vs cognitively normal participants, a 3-diagnostic-category ; simultaneous inference statistics were estimated using the multcomp package. 19 3 | RESULTS
| Study participant characteristics
Study participant characteristics are summarized in Table 1 . The study sample included 305 individuals with normal cognition, 22 individuals with aMCI, and 94 individuals with AD. Study groups had generally similar characteristics regarding sex, BMI, and education.
To characterize this sample, we examined these participant characteristics in relation to CSF cortisol and CSF NE. Linear regression analysis showed that both CSF cortisol and CSF NE increased significantly with participant age (P < .0001) by a mean ± SE of 0.7 ± 0.1 ng/mL (95% CI, 0.5-0.9 and 8.4 ± 2.1 pg/mL (95% CI, 4.3-12.4) per 10 years of participant age increase, respectively. Adjusting Slopes are estimated from linear regression of cortisol on age and diagnostic category. A, CSF cortisol increases with age and is higher in AD/aMCI than in normal controls (P < .001). B, CSF NE increases with age but is not affected by AD/aMCI (P > .70). AD, Alzheimer disease; aMCI, amnestic mild cognitive impairment 3.2 | CSF cortisol and NE concentrations by diagnostic category Figure 1 presents scatterplots of CSF cortisol (A) and CSF NE (B) by age with separate symbols and slopes by diagnostic category. There were significant differences in mean cortisol concentrations among controls, aMCI, and AD dementia groups adjusting for age, sex, education, and BMI. Compared with controls, CSF cortisol was higher by 1.6 ± 0.4 ng/ mL (95% CI, 0.7-2.5, P < .001) in the AD dementia group. Mean CSF cortisol for the aMCI group was higher than controls by 0.8 ± 0.7 ng/mL (95% CI, −0.8-2.5) and lower than the AD dementia group by the same amount (0.8 ± 0.7 ng/mL, 95% CI, −0.9-2.5), but neither difference was significant (P > .44). There was no significant difference in mean CSF NE among the control, aMCI, and AD dementia groups (P > .60). There was no evidence that the association between cortisol and NE differed by age (linear age by NE interaction, P = .45).
| Association between CSF cortisol and NE
However, when testing for the effect of diagnostic category on the cortisol versus NE association, a significant interaction was found (interaction term: NE by category; P = .021). In cognitively normal controls (Figure 2 ), no association between CSF cortisol and NE was found The linear regression model above was used to calculate mean cortisol levels per increased NE levels ( Table 2 ). In AD dementia participants, an increase in CSF NE from 100 to 300 pg/mL was associated with an increase in cortisol from 13.7 to 16.0 ng/mL. In aMCI participants, the same increase in CSF NE was associated with an increase in cortisol from 12.5 to 15.4 ng/mL. In contrast, cognitively normal participants' mean cortisol level remained constant with increasing NE concentrations.
| Sensitivity analyses
Sensitivity analysis using age as a nonlinear variable demonstrated similar results as the primary findings above, further confirming age does not explain the relationship between CSF cortisol and NE found in AD dementia patients.
Another sensitivity analysis using regression models using log(NE)
instead of NE as the dependent variable to address right skewness in the NE variable also yielded similar findings. When a participant with cortisol >30 ng/mL was excluded, differences in mean cortisol between the controls and aMCI and AD groups remained significant.
However, the exclusion of this participant attenuated the difference in the cortisol vs NE slopes by diagnostic category (NE by diagnostic category interaction P = .079).
When diagnostic category was modeled with 2 categories (AD dementia and aMCI combined vs controls), diagnostic category differences in mean cortisol and in the cortisol vs NE slopes were strengthened. Mean CSF cortisol for the AD/aMCI group was higher than controls by 1.3 ± 0.4 ng/mL (P < .001). Mean CSF cortisol increased by 1.2 ± 0.3 ng/mL per increase in CSF NE of 100 pg/mL, (P = .002, NE by category interaction; P = .007). These associations remained significant with the exclusion of the high cortisol outlier.
| DISCUSSION
This analysis is the first, to our knowledge, to examine the association between CSF cortisol and CSF NE in cognitively normal controls, participants with aMCI, and participants with AD dementia. We show that contrary to our hypothesis, there was not a significant positive association between CSF cortisol and CSF NE in control participants. In contrast, we did find a positive association between CSF cortisol and CSF NE in AD dementia participants, a finding strengthened when the aMCI and AD dementia participants were combined in the analysis.
Although stimulatory regulation of the HPA access by central noradrenergic system input is well established, this mechanism is one among multiple neural and endocrine regulators of the HPA axis. These range from direct projections and indirect paths between brain structures, signaling through peripheral sympathetic input, and glucocorticoid negative feedback. 2, 22 Given the complexity of the relationships between these 2 stress systems, it is not surprising that we did not find the association between CSF cortisol and CSF NE in controls we had anticipated. These multiple regulatory mechanisms likely obscure finding a significant relationship between CSF NE and CSF cortisol, particularly as the latter hormone is derived from the periphery and must cross the blood brain barrier.
There are several phenomena in AD that could increase the likelihood of detecting a significant relationship between NE and cortisol, one of which is the blood brain barrier. Normally, access of cortisol to the CNS is restricted by tight junctions and by efflux transporters, the primary of which is P-glycoprotein. 23 In AD, P-glycoprotein has been shown to be expressed at lower levels and have decreased function; tight junctions are loosened, and focal necrosis also increases permeability of the blood brain barrier. [24] [25] [26] Together, these changes provide greater access to the brain and CSF but decrease the efficiency of cortisol efflux, likely resulting to higher CSF cortisol in those with AD. This process in AD would favor detection of a significant association between NE and cortisol in the CSF compartment.
Another possibility is raised by demonstration in preclinical studies that chronic stress enhances PVN excitability, through multiple mechanisms including reduction of feedback inhibition and increased input from afferent connections. 22 One such mechanism involves the noradrenergic system, as chronic stress enhances noradrenergic innervation. 1 Norepinephrine has been suggested to play a key role in chronic stress enhancement of HPA axis excitability. 27 It is likely that the impaired memory, executive function, and reasoning ability of AD patients make everyday challenges more stressful. Such elevations in chronic stress could give the noradrenergic component of HPA axis stimulatory regulation a more dominant role and thus make a relationship between CSF NE and CSF cortisol more detectable in this study.
Finally, there are known alterations in the noradrenergic system in AD. 28 Marked degeneration of the LC is one of the earliest changes that occur in the course of AD, 7,29-31 and more recently, accumulation of tau in the LC has been found to occur early in AD as well. 8 Postmortem studies indicate increased biosynthetic capacity in remaining LC neurons 9 and upregulation of numbers of postsynaptic alpha-1 adrenoreceptors present in AD patients compared with controls in the hippocampus and frontal cortex. 10, 32 We have previously proposed that this apparent compensatory upregulation contributes to symptoms such as agitation and aggression in AD. 12, 33 How these changes in AD may influence HPA axis activation is less clear. In animal studies, LC projections to the PVN are present, although the substantial proportion noradrenergic input comes from the nucleus of the solitary tract. 22 There also may not be detectable differences in NE measured in the hypothalami of AD subjects compared with controls. 34 However, given the early and substantial changes in the noradrenergic system in AD, as well as our previous work suggesting compensatory upregulation of this system, an alteration in the relationship between CSF NE and cortisol compared with controls is a consistent finding, notwithstanding uncertainty over the exact mechanism by which this association occurs.
One separate area of significance of this study is that it replicates several other previous CSF studies. We show that higher cortisol concentrations occur in older versus younger adults and in AD patients versus controls. 4, 5, 35, 36 We had previously demonstrated in this sample that CSF NE increases with age; the analysis described in this report also replicates smaller studies revealing similar CSF NE concentrations in controls and AD participants. 33, 37 There are several limitations to this study. It is a cross-sectional examination of stress systems known to fluctuate depending on the time of day and environment. To minimize this variability, the study design standardized lumbar puncture procedures including time of day and included a large number of participants in relation to most CSF studies, which better accommodates variability. This study also may not have taken into account potential medication effects, although we excluded participants taking medications known to affect CSF NE or cortisol levels (eg, certain antidepressants and Parkinson disease medications). Another limitation is that this analysis presents associations only and does not elucidate mechanisms. However, associations seen in this study provide rationale for future work investigating underlying pathophysiology.
In summary, this study reports a positive association between CSF cortisol and CSF NE levels in AD patients but not in cognitively normal controls. This association likely reflects alterations in the HPA axis and noradrenergic systems in the CNS of AD patients. Given the complexity of the relationships between these 2 systems, we propose several possible mechanisms ranging from how cortisol is cleared from the CSF to neurobiological changes in chronic stress and AD. The underlying mechanism of this association may not be clear from this study alone, but findings support future studies examining the relationships between these 2 stress systems in AD.
